Our Investors

Established in 2010, LNC Therapeutics has already raised €22.7M.

Key facts:

We are backed by renowned and valuable investors.

Seventure Partners / Health For Life Capital, Europe’s leading microbiome innovation investment fund, is our historic lead investor.

Three family offices have also backed LNC, as well as public investors, including the Nouvelle Aquitaine region. We also received support from BPI France.


To achieve our ambitious strategy to become a leading biotech company in the development of microbiome-based therapies, we are open to welcome new investors in our portfolio.

Want to talk to our CEO?

Microbiome & us
Sep 8, 2020
LNC Therapeutics Receives FDA Investigational New Drug Approval to Initiate a Phase 1 Clinical Trial on Xla1 for the...
> more
Apr 15, 2020
LNC Therapeutics announces the acquisition of an exclusive worldwide license on the first patent related to...
> more
Press / Media
Nov 12, 2019
Biotechs investments disrupt Big Pharma business model The pharmaceutical industry is in a state of flux, with...
> more
Sep 6, 2019
Chaque semaine, Maddyness dresse le bilan des levées de fonds de la semaine qui vient de s’écouler. Cette semaine,...
> more
Apr 22, 2020
Keystone gut bacteria are the foundation of the whole microbial ecosystem because they provide very specific metabolic...
> more
Dec 6, 2019
The term “microbiome” refers to the collection of microorganisms (or microbiota) – including bacteria, viruses and...
> more
now on twitter
LNC Therapeutics

Could microbiome predict the severity of illness among those exposed to the virus? #GutMicrobiome #Covid19

LNC Therapeutics © 2020 - all rights reserved terms and conditions